Director at SI-BONE (SIBN) granted 10,957 restricted stock units
SI-BONE, Inc. director Jeryl L. Hilleman was granted 10,957 restricted stock units (RSUs) as director compensation, which will vest 100% on the earlier of the company’s next annual general meeting or one year from the vesting commencement date, contingent on continued board service. These RSUs were granted at $0.00 per share and are not an open-market purchase. Following this award, Hilleman's direct holdings now total 43,772 shares of common stock, including the unvested units.
SI-BONE extends headquarters lease and reports annual meeting voting results
SI-BONE, Inc. has extended its headquarters lease for one month, with an option for an additional month, for its Santa Clara, California office. The company also announced the results of its annual meeting, where shareholders elected two directors, ratified the appointment of its independent accounting firm, and approved executive compensation. These developments follow a recent financial report where SI-BONE exceeded EPS forecasts but slightly missed revenue, subsequently raising guidance.
SI-BONE (SIBN) director granted 10,957 RSUs in new equity award
SI-BONE, Inc. director Mika Nishimura was granted 10,957 restricted stock units (RSUs) of common stock at no cash cost. These RSUs will vest 100% upon the earlier of the next annual stockholder meeting or one year from the vesting start date, provided she remains on the Board. Following this award, Nishimura directly holds a total of 43,673 shares, including these unvested units.
SI-BONE (SIBN) director granted 10,957 restricted stock units and reports holdings
SI-BONE, Inc. director John Gordon Freund was granted 10,957 restricted stock units (RSUs) at $0.00 per share as compensation. These RSUs will vest 100% on the earlier of the next annual general meeting or one year from the vesting commencement date, contingent on his continued board service. Following this grant, Freund directly holds 54,258 shares and is associated with 91,767 shares held indirectly through a family partnership.
Si-Bone director Jeffrey Dunn sells $54.5k in stock
SI-BONE director Jeffrey W. Dunn sold 3,575 shares for $54,505 to cover tax obligations related to vested restricted stock units (RSUs). This sale followed his acquisition of 10,957 shares from RSU settlements. After these transactions, Dunn directly holds 16,057 shares and indirectly holds 81,073 shares through a trust.
SI-BONE (SIBN) director receives 10,957-share restricted stock grant
SI-BONE, Inc. director Thomas A. West was granted 10,957 shares of common stock in the form of restricted stock units at no cash cost. Following this award, his direct holdings total 37,947 shares, including previously granted RSUs. The new RSUs will vest 100% upon the earlier of the company's next annual general meeting or one year from the vesting commencement date, conditional on his continuous service on the Board.
SI-BONE (SIBN) director awarded 10,957 RSUs, total holdings 76,679 shares
SI-BONE, Inc. director Timothy E. Davis Jr. was awarded 10,957 restricted stock units (RSUs) in a recent transaction, bringing his total direct holdings to 76,679 shares, including these new RSUs. These RSUs, which represent a contingent right to receive one share of common stock each, will vest 100% on the earlier of the next annual general meeting or one year from the vesting commencement date, contingent on his continued service on the board. The transaction was reported in a Form 4 filing, indicating an equity-based compensation grant with a reported price of $0.00 per share.
Technical Reactions to SIBN Trends in Macro Strategies
This article analyzes Si-bone Inc. (NASDAQ: SIBN) using AI models, identifying a positive near-term sentiment while broader alignment remains weak, characterized by a mid-channel oscillation pattern. It presents three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored to different risk profiles, along with multi-timeframe signal analysis and specific entry, target, and stop-loss levels for SIBN.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. The company, a leader in procedural solutions for compromised bone, will host a fireside chat on June 16, 2026. Investors can register to listen to the webcast, which will also be archived on SI-BONE's website.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. The company's management will host a fireside chat on June 16, 2026, at 5:40 a.m. PT/8:40 a.m. ET. Investors can register to listen to the conference call via webcast on the company's website.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. Management will host a fireside chat on June 16, 2026, at 5:40 a.m. Pacific Time/ 8:40 a.m. Eastern Time. Interested investors can register to listen to the webcast via the company's website.
SI-BONE To Present at Truist Securities 2026 MedTech Conference on June 16, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. Management will host a fireside chat on June 16, 2026, at 5:40 a.m. Pacific Time/8:40 a.m. Eastern Time. Investors can register for the live webcast or access the archived replay on the company's website.
Medtech firm SI-BONE plans Truist fireside chat June 16
SI-BONE (Nasdaq:SIBN) announced its participation in the 2026 Truist Securities MedTech Conference in Boston, MA. Management will host a fireside chat on June 16, 2026, at 5:40 a.m. PT / 8:40 a.m. ET. A live audio webcast and a 90-day replay will be available on the company's investor website for interested investors.
Si-Bone director Davis Jr sells $104k in common stock
SI-BONE, Inc. director Timothy E. Davis Jr. sold $104,186 worth of common stock in late May after exercising stock options. The sales occurred at prices between $14.12 and $14.505 per share. Despite the insider sale, analysts view SI-BONE as undervalued, with price targets ranging from $18 to $32, and the company recently reported strong Q1 2026 financial results with revenue growth and a narrower net loss than expected.
Si-Bone director Davis Jr sells $104k in common stock
SI-BONE director, Timothy E. Davis Jr., sold common stock worth $104,186 over two days in late May, following the exercise of stock options. These sales occurred at prices between $14.12 and $14.505 per share. The company's stock is currently trading near its 52-week low but is considered undervalued by analysts, with price targets set much higher.
Si-Bone director Davis Jr sells $104k in common stock
Timothy E. Davis Jr., a director at SI-BONE, Inc. (NASDAQ:SIBN), sold over $104,000 worth of common stock in late May 2026, following the exercise of stock options. These sales occurred as SI-BONE shares were trading near the lower end of their 52-week range, despite analysts' price targets suggesting undervaluation. The company recently reported strong first-quarter 2026 financial results with narrower losses and increased revenue guidance, supported by a strong cash position.
SI-BONE (SIBN) director exercises options and sells common shares
SI-BONE, Inc. director Timothy E. Davis Jr. exercised options for 12,064 shares of common stock at $4.32 per share on May 28, 2026, and subsequently sold a total of 7,280 shares (3,780 at $14.4706 and 3,500 at $14.1394) on May 28 and 29, 2026. Following these transactions, he directly holds 65,722 shares, which includes 8,675 shares related to restricted stock units. The filing indicates a moderate impact with a negative sentiment due to the net selling activity by the insider.
Wall Street analysts predict a 71.13% upside in Si-Bone (SIBN): Here's what you should know
This article mentions that Wall Street analysts are predicting a significant 71.13% upside for Si-Bone (SIBN) stock. However, the provided content is incomplete, and therefore, no further details or insights into this prediction can be extracted.
SIBN (NASDAQ: SIBN) files Form 144 for 3,500 restricted shares
SIBN (NASDAQ: SIBN) has filed a Form 144, indicating a proposed sale of 3,500 restricted common stock shares. The filing also notes a previous sale by Timothy E. Davis Jr. of 3,780 shares on May 28, 2026, for $54,698.87. Morgan Stanley Smith Barney LLC is listed as the broker for the proposed sale.
SI-BONE Inc stock (US8255921098): stable trading ahead of Q2 update and focus on spine implant growt
Shares of SI-BONE Inc (SIBN) are trading steadily on Nasdaq as investors await the Q2 update and focus on the company's spine implant growth. The article highlights investor interest in the adoption of SI-BONE's iFuse technology for sacroiliac joint fusion and pelvic fixation, noting the company's position in the minimally invasive spine procedure market. It emphasizes that while no new earnings were released on May 29, 2026, the trading pattern reflects anticipation of future procedure volumes, surgeon onboarding, and international expansion.
SI-BONE's strong revenue growth hasn't boosted its share price, raising questions about market sentiment or underlying issues. Caution is advised for investors, with analysts taking a neutral to slightly bearish stance until profitability or improvement is shown.
Despite SI-BONE's strong revenue growth, its share price has not seen a corresponding boost, leading to questions about market sentiment or potential underlying issues. The stock recently dropped 12% in a week, contributing to a 39% loss over five years. Analysts currently hold a neutral to slightly bearish outlook, advising caution for investors until the company demonstrates profitability or significant improvement.
SI-BONE (SIBN) CEO Laura Francis sells 14,957 shares to cover RSU tax bill
SI-BONE, Inc.'s CEO, Laura Francis, sold 14,957 shares of common stock on May 18, 2026, to cover tax withholding obligations associated with vesting restricted stock units. These sales were non-discretionary, executed at weighted average prices around the mid-$14 range. Following the transactions, Francis directly holds 540,476 shares and indirectly holds 378,682 shares through a family trust, maintaining significant equity exposure in the company.
SI-BONE (SIBN) legal chief sells 3,726 shares in tax sell-to-cover
Michael A. Pisetsky, SI-BONE's SVP and Chief Legal Officer, sold 3,726 shares of common stock on May 18, 2026, for approximately $14.63 per share. These transactions were "sell to cover" sales to meet tax obligations from restricted stock unit vesting, not discretionary trades. Pisetsky still holds 1,395 shares from an employee stock purchase plan and 143,729 shares awaiting settlement from restricted stock units.
Tax-related SI-BONE (SIBN) CFO sale of 4,666 shares disclosed
Anshul Maheshwari, CFO of SI-BONE, Inc. (SIBN), sold 4,666 shares of common stock in two transactions at weighted average prices of $14.6545 and $14.7132 per share. These sales were explicitly identified as "sell to cover" transactions to meet tax withholding obligations for vested restricted stock units, not discretionary trades. Maheshwari retains a substantial equity position, including 183,921 shares issuable from outstanding restricted stock units and 1,395 shares acquired via an Employee Stock Purchase Plan.
Si-Bone CEO Laura Francis sells $220,000 in company stock
Laura Francis, CEO of SI-BONE, Inc., sold 14,957 shares of company stock worth $220,000 on May 18, 2026. These "sell to cover" transactions were made to satisfy tax obligations related to restricted stock units, not as discretionary trades. Following the sales, Ms. Francis continues to hold significant direct and indirect shares in the company, which recently reported strong Q1 2026 financial results, beating EPS forecasts despite slightly missing revenue.
Earnings call transcript: Si-Bone Q1 2026 beats EPS forecast, stock rises
SI-BONE, Inc. reported strong first-quarter 2026 financial results, with EPS of -$0.10 significantly beating the forecast of -$0.19, and revenue reaching $52.6 million. The company's stock rose in aftermarket trading, reflecting investor confidence fueled by an 11.2% year-over-year revenue growth, high gross margins, and strategic initiatives in product innovation and market expansion. Si-Bone also provided an optimistic outlook, raising its full-year guidance and highlighting potential tailwinds from new product launches and favorable reimbursement changes.
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. (Nasdaq: SIBN) announced its financial results for the first quarter of 2026, reporting worldwide revenue of $52.6 million, an 11.2% increase year-over-year, and improved net loss and adjusted EBITDA. The company also raised its full-year 2026 revenue guidance to between $230 million and $233 million, reflecting confidence in its product pipeline and market expansion. Key operational highlights included growth in active U.S. physicians and international launches of new products.
SI-BONE stock (US8255921098): Q1 beat and raised FY26 guidance drive gains
SI-BONE Inc. reported better-than-expected Q1 2026 financial results and raised its full-year 2026 sales guidance, with the midpoint now exceeding consensus estimates. This positive news has driven the stock higher on the Nasdaq, reflecting increased investor confidence. The medical device company specializes in minimally invasive spine and sacroiliac joint fusion solutions, capitalizing on the growing demand for less invasive surgical techniques.
Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report
After SI-BONE Inc. released its Q1 results, analysts have updated their forecasts for 2026, predicting US$231.6m in revenue and narrower losses per share at US$0.43. Despite the improved sentiment regarding loss estimates, the average price target for the company has been trimmed by 5.4% to US$24.13, suggesting a more pessimistic outlook on its intrinsic value. The company is still expected to experience notable revenue growth, projected to outperform the broader medical equipment industry.
SI-BONE targets $230M-$233M 2026 revenue while CMS proposes new DRGs that could add up to $50,000 per Granite procedure
SI-BONE is projecting strong revenue growth for 2026, targeting $230 million to $233 million, driven by the expanding market for its iFuse and Granite systems. The company anticipates a significant boost from proposed new Medicare Severity Diagnosis Related Groups (MS-DRGs) by CMS, which could increase reimbursement for its Granite procedure by up to $50,000 per case, potentially enhancing its market penetration and financial performance.
SI-BONE, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:SIBN) 2026-05-12
SI-BONE, Inc. has released its Q1 2026 earnings call presentation. The company reported an EPS of -$0.10, beating estimates by $0.09, and revenue of $52.59M, exceeding expectations by $1.43M with an 11.20% year-over-year increase. This presentation is provided in conjunction with their earnings call.
SI-BONE, Inc. (NASDAQ:SIBN) Q1 2026 Earnings Call Transcript
SI-BONE, Inc. (NASDAQ:SIBN) reported strong Q1 2026 results, beating earnings expectations with worldwide revenue growth of over 11%. The company raised its full-year revenue guidance to $230 million to $233 million, citing confidence in its strategic initiatives, including new product launches like Intra TI and the expansion of its pelvic trauma portfolio through a partnership with Smith & Nephew. A significant potential tailwind is the proposed new DRGs by CMS, which could increase reimbursement for spinal pelvic procedures using Granite, further establishing it as a standard of care.
Truist Lowers Price Target on SI-BONE to $18 From $20, Keeps Buy Rating Rating
Truist has lowered its price target for SI-BONE (SIBN) shares to $18 from $20, while maintaining a "Buy" rating on the medical device company. This adjustment comes despite SI-BONE's recent Q1 2026 earnings report, which indicated a narrower loss and increased revenue, alongside a raised 2026 revenue outlook. The article also notes other recent analyst actions and company news, including SI-BONE's presentation at a healthcare conference.
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) reported a smaller-than-expected loss of $0.10 per share for Q1 2026, beating the Zacks Consensus Estimate of a $0.17 loss, and also exceeded revenue estimates with $52.59 million. Despite this, the stock has underperformed the S&P 500 this year, with a Zacks Rank #3 (Hold) indicating expected market-performances in the near future. The company operates within the Medical - Instruments industry, which is currently ranked in the top 44% of Zacks industries.
SI-BONE 1Q Loss/Shr 10c >SIBN
This article reports that SI-BONE (SIBN) recorded a Q1 loss per share of 10 cents. The ticker symbol for SI-BONE is SIBN.
Si-Bone: Q1 Earnings Snapshot
Si-Bone Inc. reported a first-quarter loss of $4.3 million, or 10 cents per share. The medical device company generated $52.6 million in revenue during the period and anticipates full-year revenue to be between $230 million and $233 million. This financial update was compiled using data from Zacks Investment Research.
[10-Q] SI-BONE, Inc. Quarterly Earnings Report
SI-BONE, Inc. has filed its quarterly earnings report (Form 10-Q) for the period ended March 31, 2026. The company reported a net loss of $4.3 million for the quarter, an improvement from $6.5 million in the same period last year, with revenue increasing by 11.2% to $52.5 million driven by higher U.S. procedure volumes. SI-BONE highlights its focus on expanding solutions for compromised bone, physician engagement, employee experience, and operational efficiency, while also detailing its financial position, including cash and marketable securities of $144.7 million and outstanding debt of $35.6 million.
SI-BONE (NASDAQ: SIBN) lifts 2026 outlook after double-digit Q1 growth
SI-BONE, Inc. (NASDAQ: SIBN) reported strong first-quarter 2026 results, with worldwide revenue growing 11.2% to $52.6 million and a significant improvement in adjusted EBITDA to $2.5 million. Following this performance, the company raised its full-year 2026 revenue guidance to between $230 million and $233 million, implying 14-16% growth, and increased its gross margin expectation to approximately 79%. These results and increased outlook demonstrate the company's solid operational leverage and expanding market presence.
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. announced strong financial results for the first quarter of 2026, reporting worldwide revenue growth of 11.2% to $52.6 million and a significant improvement in adjusted EBITDA to $2.5 million. The company also raised its full-year 2026 revenue guidance to between $230 million and $233 million, citing record physician engagement and successful new product launches. Key operational highlights included expanding international presence and a proposed CMS rule change that could positively impact reimbursement for complex spinal fusion procedures utilizing SI-BONE's products.
Si-Bone: Q1 Earnings Snapshot
Si-Bone Inc. (SIBN) reported a first-quarter loss of $4.3 million, or 10 cents per share. The medical device company, based in Santa Clara, California, announced revenues of $52.6 million for the period and projects full-year revenue to be between $230 million and $233 million. This information was generated using data from Zacks Investment Research.
Number of shareholders of SI-BONE, Inc. – SWB:2K3
This article provides the number of shareholders for SI-BONE, Inc., traded under the ticker SWB:2K3 on the Stuttgart Stock Exchange. The content appears to be a stub or data placeholder, focusing primarily on the company's financial overview and market information from TradingView. It also acknowledges the data providers involved.
First Light, Mathew Arens disclose 18% stake in SI-BONE (NASDAQ: SIBN)
First Light Asset Management, LLC and Mathew P. Arens have jointly reported a significant beneficial ownership stake in SI-BONE, Inc. (NASDAQ: SIBN). First Light now holds 18.02% of the company's shares, while Mr. Arens, who controls First Light and holds additional direct shares, has an attributable ownership of 18.36%. This Schedule 13G/A amendment indicates a passive investment, not an attempt to change corporate control.
Earnings Preview: Si-Bone to Report Financial Results Post-market on May 11
This article announces that Si-Bone (SIBN) is scheduled to release its financial results after the market closes on May 11. The article implies that this upcoming earnings report will be closely watched by investors and analysts.
SI-BONE (SIBN) director Dunn sells small stake to cover RSU taxes
SI-BONE, Inc. director Jeffrey W. Dunn sold 337 shares of common stock on May 4, 2026, at a weighted average price of $13.1508. This non-discretionary "sell to cover" transaction was solely to satisfy tax withholding obligations related to the vesting of restricted stock units. After the sale, Dunn directly holds 9,157 shares (including 8,675 RSU-issuable shares) and indirectly holds 80,591 shares through a living trust.
Price-Driven Insight from (SIBN) for Rule-Based Strategy
The article provides a price-driven analysis of Si-bone Inc. (NASDAQ: SIBN) for rule-based trading strategies, highlighting weak sentiment across all horizons supporting a short bias. It details three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis, showing weak signals across near-term, mid-term, and long-term horizons.
Hussman Strategic Advisors Inc. Purchases Shares of 84,000 SiBone $SIBN
Hussman Strategic Advisors Inc. acquired 84,000 shares of SiBone (NASDAQ:SIBN) in the fourth quarter, establishing a new stake valued at approximately $1.66 million, which represents a 0.19% ownership. This comes amid significant insider selling totaling $2.55 million over the past three months, reducing insider holdings to 4.0%. Despite insider sales, SiBone exceeded Q4 EPS estimates, and analysts maintain a "Moderate Buy" rating with a target price of $24.00.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 BofA Securities Healthcare Conference. Management will host a fireside chat on May 12, 2026, at 8:00 a.m. Pacific Time. Investors can register via a provided link or listen to the webcast on the company's website.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE (Nasdaq: SIBN) announced it will participate in the BofA Securities 2026 Healthcare Conference in Las Vegas, NV, on Tuesday, May 12, 2026. Management will host a fireside chat at 8:00 a.m. PT / 11:00 a.m. ET, with live audio available via webcast on the company’s investor relations page. The webcast will also be archived for at least 90 days for replay.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SI-BONE, Inc. (Nasdaq: SIBN) announced its participation in the 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will host a fireside chat on May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time. A live audio webcast will be available on the company’s website, with an archive available for replay for at least 90 days.
Impax Asset Management Group plc Has $23.66 Million Stock Holdings in SiBone $SIBN
Impax Asset Management Group plc increased its stake in SiBone (NASDAQ:SIBN) by 17.1% in the fourth quarter, bringing their total holdings to $23.66 million. Other institutional investors have also adjusted their positions in SiBone, with 98.11% of the stock owned by institutional investors and hedge funds. Despite some insider selling, analysts maintain a "Moderate Buy" consensus rating for SiBone, with an average target price of $24.00.
